Tuesday, 21 January 2020

Global Automatic Pill Dispenser Market Analysis 2019 Forecasts to 2023

Global Automatic Pill Dispenser Market Research Report: Information by Type (Centralized Automated Dispensing System, Decentralized Automated Dispensing System), End User (Hospital Pharmacy, Retail Pharmacy, Home Healthcare) and Region - Global Forecast till 2024
Automatic Pill Dispenser Market Highlights:
The Global Automatic Pill Dispenser Market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 1,700 million in 2018 and is projected to register a CAGR of 7.3% over the forecast period.
The increasing prevalence of cardiovascular disorders and growing older population are the key factors driving the automatic pill dispenser market. As per the report published by the Centers for Disease Control and Prevention (CDC) in 2017, nearly 92.1 million adults were dealing with at least one type of cardiovascular disease.
Various other factors such as the advancements in automatic pill dispenser, increasing geriatric population, untapped emerging markets, rise in regulatory approvals, and increasing investment on home care centers are also expected to propel the growth of the market.
However, the high cost of the system can hamper market growth over the forecast period.
Key Players:
Some of the key players in the global automatic pill dispenser market are Baxter International Inc, Becton, Dickinson and Company, Cerner Corporation, Capsa Healthcare, McKesson Corporation, Omnicell Inc., ScriptPro LLC, Swisslog Holdings AG, Yuyama Co.Ltd. Talyst, Inc., and others
Segmentation:
The global automatic pill dispenser market is segmented based on type, end user, and region.
The global market for automatic pill dispenser, by type, is segmented into a centralized, automated dispensing system, and decentralized the automated dispensing system. The centralized, automated dispensing system is further classified into robotic automated dispensing systems, and carousels. Furthermore, decentralized automated dispensing system is classified into a pharmacy-based automated dispensing system, ward-based automated dispensing system, and automated unit dose dispensing system.
Based on end user, the market is segmented into hospital pharmacy, retail pharmacy, and home healthcare.
In the current scope of the study, the segments mentioned above are covered into the four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and African region.
The automatic pill dispenser market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European automatic pill dispenser market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The automatic pill dispenser market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The automatic pill dispenser market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Analysis:
The Americas dominated the global market for automatic pill dispenser owing to the rising geriatric population within the region. As per the data suggested by the United Census Bureau, by 2060, the US is projected to grow by 79 million people, from about 326 million today to 404 million. The population is projected to cross the 400-million threshold in 2058. Additionally, according to the WHO, in the US, more than 20% of the total population is likely to be aged 65 years or over by 2030. Rising participation of market players is also strongly impacting the growth of the Americas automatic pill dispenser market. Moreover, the rising prevalence of chronic disorders such as cardiovascular disorders, cancer, diabetes, and others are driving the growth of the market. For instance, according to the National Cancer Institute, in 2016, in the US, 15.5 million new cases of cancer were registered, and approximately USD 147.3 billion were spent for cancer care.
In 2018, it was estimated that Europe stood second in the global automatic pill dispenser market. Technological advancements, along with the availability of funding opportunities in research and innovation, will support market growth.
Asia-Pacific (APAC) is expected to represent the phenomenal market growth throughout the forecast period due to rising prevalence of chronic conditions, growing awareness about medications, and increasing healthcare expenditure. During 2016-2017, Australia spent nearly USD181 billion on health, which is more than USD 7,400 per person and 10% of overall economic activity.
On the other hand, the Middle East and Africa held the least share in the global automatic pill dispenser market due to the low economic development, especially within the African region.
Posted by at No comments:
Labels:

Global Chemotherapy Market Trends, Demand and Forecast to 2023

Global Chemotherapy Market: Information by Drug Class (Alkylating Agents, Mitotic Inhibitors, Antimetabolites, Topoisomerase Inhibitors and Antitumor Antibiotic), Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Lymphoma, Leukemia and Ovarian Cancer), Route of Drug Administration (Intravenous, Oral, Subcutaneous, Intra-Muscular, Intravesicular, Topical, Intraperitoneal and Intraventricular/Intrathecal) and End-User (Specialty Centers and Hospitals & Clinics) - Global Forecast till 2024
Market Scenario:
Chemotherapy Market 2019 offered by Market Research Future (MRFR), The Global Chemotherapy Market is Expected to register a CAGR of 11.50% to reach USD 56,491.59 Million by 2024. Global Chemotherapy Industry by Drug Class, Indication, Route of Drug Administration and End-User and Forecast till 2024
The increasing prevalence of cancer, increasing expenditure on oncology medicine and research, and reimbursements and growing health insurance are driving the growth of the global chemotherapy market. 
Market Dynamics
The global Chemotherapy Market Growth has been largely benefited by the increasing demand for chemotherapy products across the world. Increasing prevalence of cancer; increasing expenditure on oncology medicine and research, and reimbursements and growing health insurance are expected to spur market growth during the forecast period. Moreover, the patent expiry of leading drugs, government initiatives, and increasing public awareness about various diseases and treatment options are further expected to boost the growth of the global chemotherapy market during the review period.
Chemotherapy is one of the types of cancer treatment, which includes the use of one or more chemotherapeutic agents such as anti-cancer drugs. The treatment prevents the division of cancer cells and the growth of cancer cells by killing dividing cells. It is used for the treatment of various types of cancers such as lung cancer, breast cancer, leukemia, myeloma, sarcoma, lymphoma, ovarian cancer, and others.
Segmentation
The Global Chemotherapy has been segmented into major four segments, including drug class, route of administration, indication, and end user.
On the basis of drug class, the market is segmented into alkylating agents, mitotic inhibitors, antimetabolites, topoisomerase inhibitors, and antitumor antibiotic. The alkylating agents segment is expected to lead the market and register a substantial CAGR to reach USD 20,360.32 million by the end of 2024 and projected to exhibit the highest CAGR of 11.83% from 2019 to 2024.
Furthermore, based on indication, the market is segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach cancer, lymphoma, leukemia, ovarian cancer, and others.  Lung cancer accounted for the largest market share and expected to grow with the CAGR of 11.88% during the forecast period.
On the basis of route of administration, the market is segmented into intravenous, oral, subcutaneous, intra-muscular, intravesicular, topical, intraperitoneal, and intraventricular/intrathecal. Intravenous accounted for the largest market share. However, the oral segment is expected to grow at the fastest CAGR of 11.95% during the forecast period.
On the basis of end user, the market is segmented into, specialty centers, hospitals & clinics, others
Key Players
The prominent players in the global chemotherapy market are Johnson & Johnson Services Inc (US), GlaxoSmithKline PLC (UK), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Pfizer Inc. (US), Merck & Co. Inc. (US), Sanofi S.A. (France), Celgene Corporation (US) and Bristol-Myers Squibb Company (US).
Regional Analysis
Geographically the chemotherapy market is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
Americas accounted for the largest market share of 41.04% in 2018, and the regional market is projected to register a CAGR of 10.88%during the forecast period. North America is one of the leading markets in the region, accounting for the largest market share during the review period.  
The European market is estimated to exceed USD 18,292.73 Million by 2024. The accessibility to advanced treatment facilities, rising government initiatives to promote research to find a cure to the increasing number of cancer cases, and growing healthcare expenditure are driving the growth of the chemotherapy market in the region. Germany is the major contributor to the growth of the regional market, followed by France.
The market in Asia-Pacific is expected to be the fastest growing market. This high growth is mainly attributed to the increasing R&D funding by developing countries such as China and India for the development of the healthcare sector. Various other factors that influence the growth of the market include growing incidence of cancer, aging population, increasing demand for advanced therapies, patent expiry of leading drugs, government initiatives, and increasing public awareness about various diseases and treatment options.
The Middle East & Africa commands the least market share of the chemotherapy market, owing to fewer developments and extremely low income but, is expected to grow with better chemotherapy treatments. As the population is rapidly aging, cancer treatment is expected to increase in this region
Posted by at No comments:
Labels:

Global Tele-Intensive Care Unit (ICU) Market 2019 Study and Analysis Research Report Forecast To 2023

Global Tele-Intensive Care Unit (ICU) Market: Information by Component (Component, Software), Type of Management (Intensivist ,Open, Co-managed, Open with Consultant and other Types of Management) and Region - Global Forecast till 2024
Tele-Intensive Care Unit (ICU) Market Scenario
Tele-Intensive Care Units (ICU) are advanced systems used for the treatment of critically ill patients by using off-site clinical resources. It is a part of telemedicine which is used for the exchange of medical information for conducting various medical activities such as monitoring, treatment, and rehabilitation.
The Global Tele-Intensive Care Unit (ICU) Market is accounted for USD 1820 Million in 2018 and expected to register 16.4% CAGR during the forecast period (2019–2024).
The rising prevalence of chronic disorders such as cancer, increasing geriatric population, technological advancements in the healthcare sector and increasing cases of patients affected by neurological disorders across the world are expected to drive the growth of the market. For instance, according to the Centers for Disease Control and Prevention (CDC), In the year 2016, more than 10.4 million cases of tuberculosis were registered in the world, and 1.7 million deaths occurred due to tuberculosis in the year 2016. Moreover, rising R&D spending and aggressive strategies adopted by the top players, such as new product launches, are contributing to the growth of the market.
The lack of adequate reimbursement policy and high costs involved in the establishment of these centers may hamper the growth of the market during the assessment period.

Tele-Intensive Care Unit (ICU) Market Segmentation

The global Tele-Intensive Care Unit (ICU) market has been segmented on the basis of component and type of management.
On the basis of component, the market has been classified as hardware and software. The market, by hardware, has been further segmented into the computer system, communication lines, physiological monitors, therapeutic devices, video feeds, and others.
Based on the type of management, the market has been segmented into intensivist, open, co-managed, open with a consultant, and other types of management.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Tele-Intensive Care Unit (ICU) market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European Tele-Intensive Care Unit (ICU) market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The Tele-Intensive Care Unit (ICU) market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Tele-Intensive Care Unit (ICU) market in the Middle East & Africa has been segmented into the Middle East and Africa.

Tele-Intensive Care Unit (ICU) Market Company Profiles

  • SOC Telemed
  • Intouch Technologies, Inc.
  • Koninklijke Philips N.V.
  • Advanced Icu Care
  • UPMC
  • Banner Health
  • Teleicucare
  • Eagle Telemedicine
  • Apollo TeleHealth Services
  • Inteleicu
  • Others
Tele-Intensive Care Unit (ICU) Regional Market Summary
The Americas are likely to dominate the global Tele-Intensive Care Unit (ICU) market owing to the technological advancements related to healthcare in the region, the surge in cases of chronic disorders, and an increasing number of hospitals in the regions.  According to the report published by the American Hospital Association, more than 5200 community hospitals were present in the US in the year 2018, out of which 3,387 belongs to urban areas, and 1875 were from rural areas.
The European market is expected to be the second-largest Tele-Intensive Care Unit (ICU) market. The market growth in this region can be attributed to the increasing demand of healthcare systems which can provide real-time data, rising cases of neurological disorders in the European region, and government funding and support of the healthcare sector along with the increasing research and development. Moreover, favorable reimbursement policies in European countries are contributing to the growth of the market in this region. According to the European Academy of Neurology, neurological disorders are increasing in Europe, and in the year 2017, more than 220 million European population was affected by neurological complications.
Asia-Pacific is expected to be the fastest-growing Tele-Intensive Care Unit (ICU) market during the forecast period owing to the increasing geriatric population, rising investments in healthcare, and expansions by market players in the region. Also, countries such as India and China are considering the fastest growing region due to the presence of a huge patient population. Moreover, the government of these countries is open to adopting new technology and the best treatment option from a developed country.
The market in the Middle East & Africa is expected to account for the smallest share of the global Tele-Intensive Care Unit (ICU) market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Posted by at No comments:
Labels:

Gene Expression Analysis Market Competitive landscape By 2023

Gene Expression Analysis Research Report: Information by Product (Consumables & Instruments), Service (Gene Expression Profiling & Others), Application (Drug Discovery & Others), End User (Academic & Research Institutes & Others) - Forecast till 2023
Market Scenario:
The Global Gene Expression Analysis Market is expected to grow significantly over the forecast period. It is estimated that the global gene expression analysis market is expected to hold a market value of USD 3.250 million and register a CAGR ~9.1% during the forecast period of 2018 to 2023. Gene expression analysis is research dedicated towards functional genomics extending the application purview of studying genes and gene transcripts. Synthesizing functional gene products such as functional RNAs and protein species offers insights on how an intact organism survives when a particular gene goes missing. Growth in personalized medicine and technological developments are driving market growth. According to a data published by the Foley & Lardner LLP, Food and Drug Administration (FDA) approved 16 new personalized medicines in 2017. Moreover, the development of genomic databases and increased government funding towards genomics is fueling market growth.
However, the lack of skilled labor and the high cost of instruments may hamper market growth during the assessment period.
Segmentation
The global gene expression analysis market has been segmented into product, services, application, end-user, and region.
The market, on the basis of product, has been segmented into consumables and instruments.
The market, based on consumables, has been further segmented into reagents and DNA chips.
The market, based on instruments, has been further segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), microarray, Sanger sequencing, and others.
The market, by services, has been segmented into gene expression profiling services, sequencing services, bioinformatics solutions, and others.
The market, by application, has been segmented into drug discovery, diagnosis, research, and others.
The market, by end-user, has been segmented into pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The gene expression analysis market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European gene expression analysis market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The gene expression analysis market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The gene expression analysis market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key Players
Some of the key players in the global gene expression analysis market are GENERAL ELECTRIC COMPANY, Illumina, Inc., Thermo Fisher Scientific, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Pacific Biosciences of California, Inc., BGI, PerkinElmer Inc., Agilent Technologies, Inc., QIAGEN, Oxford Gene Technology, Eurofins Scientific, Danaher, Genotypic Technology Pvt Ltd, Macrogen Inc.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global gene expression analysis market owing to the increasing research activities and the rising popularity of gene expression tests. Additionally, the well-developed healthcare sector is anticipated to boost the American gene expression analysis market.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the growing investment from governments in the field of genomics, and continuously developing economies. According to a report published by the International Journal of Social and Developmental Concerns in October 2017, in Malaysia, the growth of the public primary, as well as secondary care facilities, has decreased in the past few years, and it has not kept pace with the rapid urbanization. Thus, such factors restraint the growth of the market in this region. On the other hand, the Middle East & Africa has the least share of the market.
Europe is expected to hold the second largest position in the global gene expression analysis market. The market growth in this region is attributed to the availability of funds for research.
Posted by at No comments:
Labels:

Robot-Assisted Surgical Systems Market Global Sales, Revenue, Price and Gross Margin Forecast To 2023

Global Robot-Assisted Surgical Systems Market Research Report, by Product (Surgical Robot, Rehabilitation Robot, Non-Invasive Radiosurgery Robot), Application (Neurology, Orthopedic, Laparoscopy), End User (Healthcare Provider, Payer) –Forecast Till 2023
Market Insights:
The increasing need for automation in the healthcare industry and the shifting trend towards advanced robotic surgeries is anticipated to fuel the growth of the market. The high initial costs and adverse reports stand is expected to hamper the growth of the market.
Robot-assisted surgical systems industry will witness a widespread adoption since the introduction of the da Vinci surgical system by Intuitive Surgical Inc. After the system got FDA approval in 2000, da Vinci surgical system became the most widely-used surgical robot in the United States and Europe helping many cases to witness reduced length of hospital stays and lower rates of infection.
The Global Robot-Assisted Surgical Systems Market is projected to grow significantly over the forecast period. It is estimated that the global robot-assisted surgical systems market is expected to register a CAGR of ~10% during the forecast period of 2018–2023.
The global robot-assisted surgical systems market is conquered by several players. The key players are involved in new product launches, as well as strategic collaborations to brace their position in the market. For instance, in May 2015, Medtech expanded its presence in Asia with the sales of three ROSA Surgical Robots during April. This initiative is anticipated to open new avenues for the firm to cater to the untapped markets in this region.
Key Players
  • Stryker Corporation (MAKO Surgical Corp.),
  • Renishaw Plc,
  • Varian,
  • Accuray,
  • Intuitive Surgical Inc,
  • Health robotics S.R.L,
  • Smith & Nephew Plc. (Blue Belt Technologies, Inc.),
  • Auris Surgical Robotics, Inc. (Hansen Medical Inc.),
  • KUKA AG,
  • Mazor Robotics,
  • Medtronic plc,
  • THINK Surgical Inc.,
  • Zimmer Biomet Holdings Inc.,
  • Transenterix,
  • Verb Surgical,
  • Titan Medical,
  • Microbot Medical,
  • Medrobotics
Segmentation
The Global Robot-Assisted Surgical Systems Market is segmented on the basis of product, application, and end user.
Surgical robots are divided into orthopedic surgical robots, robotic neurosurgical systems, and laparoscopy robotic systems. Orthopedic Surgical Robots is divided into an iBlock surgical system, Robodoc surgical system, Navio PFS surgical system, MAKO RIO surgical system, and Stanmore Sculptor surgical system. Neurosurgical Robotic Systems is divided into Pathfinder surgical system, NeuroMate surgical system, and Renaissance surgical system. Laparoscopy Robotic Systems is divided into FreeHand endoscope holder system, Da Vinci robotic surgery system, Telelap ALF-X surgical system, and Steerable Robotic Catheters.
The robot-assisted surgical systems market by product is categorized into surgical robots, rehabilitation robots, non-invasive radiosurgery robots, hospital and pharmacy robots, and emergency response robotic systems.
Rehabilitation robots are categorized into assistive robots, prosthetics, orthotics, therapeutic robots, and robotic exoskeleton systems. Hospital and pharmacy robots are categorized into telemedicine robots, IV robots, pharmacy robots, and cart transportation robots.
Based on application, the robot-assisted surgical systems market is segmented into neurology, orthopedics robotic systems, laparoscopy, and special education.
On the basis of end user, the market is segmented into healthcare providers, healthcare payers, and others.
On the basis of region, the global robot-assisted surgical systems market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and Latin America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, South Korea, and the rest of Asia-Pacific. The robot-assisted surgical systems market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary
It is projected that the Americas dominated the global robot-assisted surgical systems market owing to the growth of the market in the North American region. This is largely attributed to factors such as well-established healthcare infrastructure and the increase in adoption of robotic surgical systems across various healthcare settings will support market growth in this region. Europe is expected to hold the second largest share in the robot-assisted surgical systems market owing to the introduction of advanced robot-assisted laparoscopic procedures and quality of treatment of existing and new medical indications.
Asia-Pacific was projected to be the fastest growing region for the global robot-assisted surgical systems market. With the growth of the overall robotics market in the region headed by technology giants like Japan and China, the availability of medical robots has also increased. In 2017, a robot performed the world’s first automated dental implant in China. The Middle East and Africa holds the least share in the global robot-assisted surgical systems market due to the presence of economically diverse countries, and fewer initiatives taken by the government.
Posted by at No comments:
Labels:

Live Cell Encapsulation Industry Overview, Trends and Market Growth Analysis Research Report 2023

Global Live Cell Encapsulation Market Research Report: By Manufacturing Technique (Simple Dripping, Electrostatic Dripping, & Others), Polymer Type (Alginate, HEMA-MMA, Chitosan, PAN-PVC, & Others), Application (Drug Delivery & Others)-Forecast till 2023
Market Scenario:
The global live cell encapsulation market is currently dominated by many market players. The key players in the market are involved in new product launches and strategic collaborations to strengthen its market position. For instance, in August 2018, Balchem Italia S.r.l., a wholly owned subsidiary of Balchem Corporation, acquired Bioscreen Technologies, S.r.l., a privately held manufacturer of encapsulated and fermented feed nutrition ingredients. With this, the company aims to expand its position in the market.
The Global Live Cell Encapsulation Market is expected to grow significantly over the forecast period. It is estimated that the global live cell encapsulation market is expected to register a CAGR ~ 3.22% during the forecast period of 2018 to 2023, with an estimated market value of USD 249.87 million in 2017.
Numerous factors such as a high level of research activities in live cell encapsulation technologies and the rising awareness programs in various countries are anticipated to fuel the growth of the market. Moreover, the increasing investments by various public and private organizations have created a lucrative option for many companies to invest in providing new encapsulation techniques, leading to the overall growth of the market. Furthermore, the inclination towards novel drug delivery systems for disease management fuels the growth of the market during the forecast period.
However, the lack of skilled technicians, and ethical and legal issues, and unaffordability of various small-scale companies to enter the market due to high product manufacturing costs are expected to curb the growth of live cell encapsulation market. Moreover, the availability of high-quality raw material is also restraining the growth of the market.
The Global Live Cell Encapsulation Market is driven by factors such as rising demand for clinical efficacy of cell encapsulation technologies and growing awareness related to the clinical role of encapsulated cells to treat different chronic diseases. Additionally, encapsulation provides the durability and stability of the nutrient during handling and storage. Thus, such benefits of this technique are luring the competitors to enter the market.
Key Players
Balchem Corporation, Evonik Industries, Merck KGaA, BÜCHI Labortechnik AG, Lycored, Blacktrace Holdings Ltd., Living Cell Technologies, Reed Pacific Pty Limited, MiKroCaps, Biotime, Inc., Neurotech Holdings, LLC, Sernova Corporation, Encapsys, LLC, Sigilon Therapeutics, Inc., and Viacyte, Inc. are some of the key players in the global live cell encapsulation market.
Segmentation
The Global Live Cell Encapsulation Market has been segmented into manufacturing technique, polymer type, and application. The market, based on manufacturing technique, has been segmented into simple dripping, electrostatic dripping, coaxial airflow, rotating disk atomization, and others. The market, by polymer type, has been further segmented into alginate, HEMA-MMA, Chitosan, silica, cellulose sulfate, PAN-PVC, and others. The market, by application, has been segmented into drug delivery, regenerative medicine, cell transplantation, and others. The drug delivery segment is expected to hold a major share owing to the increasing use of live cell encapsulation techniques in drug delivery systems. The segment of regenerative medicine is expected to be the fastest growing segment due to the rising trend and benefits of encapsulation in the tissue engineering field.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The live cell encapsulation market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada. The European live cell encapsulation market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The live cell encapsulation market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The live cell encapsulation market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Geographically, the Americas is expected to dominate the global live cell encapsulation market due to the increasing per capita healthcare expenditure, and the heavy adoption of new technology.
Furthermore, rising expenses in research and development by healthcare bodies and the government is anticipated to drive thegrowth of the market in this region. Apart from this, increasing applications of regenerative medicine in the US is expecting to push the growth of live cell encapsulation market. For instance, According to the National Institutes of Health (NIH), approximately 5,00,000 Americans benefit from a transplant each year.
Europe showed a considerable amount of growth in the global live cell encapsulation market. The market growth in this region is because of the presence of a well-established healthcare system and increase in chronic diseases. For instance, according to cancer research UK, there were approximately 9, 921 cases of cancer diagnosed in 2015. Such high rates of cancer are likely to increase demand for the use of next-generation sequencing as well as increase the market demands for monoclonal bodies and cellular research. These factors are expected to have a positive impact on the live cell encapsulation market.
Asia-Pacific is expected to have a sturdy growth rate during the forecast period owing to the huge patient pool of chronic diseases and government initiatives of healthcare reforms. However, less capital investment is restricting the market growth of this region.
On the other hand, the Middle East & Africa has the least share of the market due to the low disposable income. Moreover, the limited adoption of advanced healthcare facilities and limited access to treatment facilities is also expected to drive the growth of the market in the near future.
Posted by at No comments:
Labels:

Soft Tissue Repair Industry Overview, Trends and Market Growth Analysis Research Report 2023

Global Soft Tissue Repair Market Research Report: By Product (Fixation, Tissue Patch/Match, & Others), Application (Orthopedic, Skin Repair, Hernia, Vaginal Sling, Dental Reconstruction), End User (Hospitals, Clinics & others)—Global Forecast till 2023
Market Insights:
The Global Soft Tissue Repair Market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 5200 million in 2017 and is projected to register a CAGR of 6.2% over the forecast period.
Various other factors such as increasing awareness about orthopedic disorders and other related conditions, improvement in reimbursement policies, untapped emerging markets, and increasing healthcare expenditure are also expected to propel the growth of the market.
The xenograft implant is designed for the surgical repair of damaged or ruptured membranes. The rising cases of sports-related injuries and technological advancements are some of the key factors driving the soft tissue repair market. For instance, in 2016, Colorado Therapeutics received FDA approval for its xenograft implant.
However, the high cost of advanced equipment and a shortage of physicians in emerging markets can hamper market growth over the forecast period.
Key Players
Some of the key players in the global soft tissue repair market are Stryker Corporation, C.R. Bard, Inc., Arthrex, Inc., Integra LifeScience Corporation, Depuy Synthes, Smith & Nephew plc, Allergan Plc., Athersys, Inc., CryoLife, Inc., Medtronic Plc., Organogenesis Inc., Zimmer Biomet Holdings, Inc., Lifenet Health, Inc., American Medical Systems Inc., U.S. Stem Cell, Inc., Wright Medical Group, Inc., Isto Biologics, and others.
Segmentation
The global soft tissue repair market is segmented based on product, application, end user, and region.
the global market for soft tissue repair, by product, is segmented into fixation products, tissue patch/match, laparoscopic instrument, and others. The fixation products segment is further classified as a suture, suture anchors, and interference screw. The tissue patch/match segment is further classified as biological, and synthetic. The biological segment includes allograft and xenograft.
Based on application, the market is segmented into orthopedic surgery, skin repair, hernia repair, vaginal sling repair, dental reconstruction, cardiovascular surgery, breast reconstruction, and others.
Based on end user, the market is segmented into hospitals, clinics, research & academic institutes, and others.
In the current scope of the study, the segments mentioned above are covered into the four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and African region.
The soft tissue repair market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European soft tissue repair market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The soft tissue repair market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The soft tissue repair market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The Americas dominated the global market for soft tissue repair owing to the increasing healthcare expenditure presence of major market players and rising geriatric population within the region. As per the data suggested by the United Census Bureau, by 2060, the US is projected to grow by 79 million people, from about 326 million today to 404 million. The population is projected to cross the 400-million threshold in 2058.
In 2017, it was estimated that Europe stood second in the global soft tissue repair market. Robust research and development (R&D) sector along with the availability of funding opportunities in research and innovation will support the market growth.
Asia-Pacific (APAC) is expected to represent the phenomenal market growth throughout the forecast period due to increasing demand for medical technology, growing health awareness, and growing aging population coupled with the rising prevalence of orthopedic diseases in India, Japan, and Australia. For instance, according to the United Nations Economic and Social Commission for Asia and the Pacific (ESCAP), in 2016, around 12.4% of the population in the region was 60 years or older and is projected to reach to more than 1.3 billion by 2050.
On the other hand, the Middle East and Africa held the least share in the global soft tissue repair market due to the low economic development, especially within the African region.
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)